Immutep S.a.s.

This study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not been treated or had stopped responding to prior therapy. The goal was to see if the combination could shrink t…

This phase 2 trial tested whether adding eftilagimod alpha to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that cannot be removed by surgery. The study included 171 participants whose tumors had certain marker…